Introducing “Let’s Talk CytoSorb® Therapy” Blog: Unveiling the Conversations that Matter
Welcome to our brand-new blog, “Let’s Talk CytoSorb® Therapy!” 📢 Here, we delve into the dynamic world of CytoSorb® therapy, exploring cutting-edge insights, clinical advancements, patient stories, and the expertise of thought leaders in the field. Join us on a journey of discovery and discussion, as we uncover the profound impact of CytoSorb® in healthcare. Let’s embark on this dialogue together, and together, let’s make a difference.
#CytoSorbTherapyBlog #MedicalAdvancements #HealthcareConversations
Stellungsnahme zur Becker Analyse
Im Rahmen dieser Studie führten Wissenschaftler am Maasstad Hospital und am Erasmus University Medical Center in Rotterdam, Niederlande, eine retrospektive Evaluation von 116 Patienten mit
CytoSorbents Expands CytoSorb Distribution in Latin America to Brazil, Colombia, and Costa Rica
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery
CytoSorbents Receives Renewal of CytoSorb® CE Mark Through May 2024 and Annual ISO 13485:2016 Certification Through September 2022
Mr. Vincent Capponi, Chief Operating Officer of CytoSorbents stated, „I am happy to announce CytoSorbents successfully completed its CE Mark and ISO13485:2016 re-certification audits.
In Bramsche neues Verfahren gegen Blutvergiftungen
Blutvergiftungen gehören zu den häufigsten Todesursachen in Deutschland. Die Bramscher Niels-Stensen-Kliniken arbeiten jetzt als eines der ersten Häuser in der Region mit einer neuen Methode,
